Bloodstream infections (BSIs) are among the most serious infections encountered in clinical practice. They can quickly progress to sepsis and septic shock, leading to high rates of morbidity and mortality if not identified and treated promptly.[1]
The cornerstone of bloodstream infection diagnosis remains blood culture. While widely used, blood cultures are limited by both sensitivity and speed. False negatives can occur due to low bacterial loads, small blood volumes collected, prior antibiotic exposure, or sample handling issues.[2] Although many cultures show positivity within 24–72 hours, some may take up to 5 days to grow. Antimicrobial susceptibility testing (AST) using conventional phenotypic methods can add additional days before results are available.[3]
This delay leaves clinicians dependent on empirical broad-spectrum antibiotics, which can contribute to resistance development and poor outcomes when the initial choice is ineffective. While molecular resistance gene assays have been adopted by some laboratories for positive blood cultures, conventional culture-based workflows still dominate in most settings.
Against this backdrop, certain pathogens frequently associated with BSIs can present particular treatment challenges.
1. Staphylococcus aureus
One of the leading causes of bloodstream infections worldwide, Staphylococcus aureus is especially concerning because of the prevalence of methicillin-resistant strains (MRSA) in many hospitals and communities.[1]
Treatment challenges: Differentiating MRSA from methicillin-susceptible S. aureus (MSSA) is critical for guiding therapy. However, conventional susceptibility testing adds delays, leaving clinicians to treat empirically until definitive results are available.[4]
2. Escherichia coli
A common Gram-negative bacterium, E. coli is responsible for many community-acquired and healthcare-associated BSIs, often originating from urinary tract or intra-abdominal infections.[1]
Treatment challenges: Extended-spectrum beta-lactamase (ESBL)-producing E. coli strains are resistant to many first-line antibiotics.[5] While the organism itself is readily cultured, identifying resistance patterns with phenotypic AST can take days—delaying effective targeted therapy.[6]
3. Klebsiella pneumoniae
Another Gram-negative pathogen, K. pneumoniae has gained notoriety due to the presence of carbapenem-resistant strains (CRE), a growing global health threat.[1]
Treatment challenges: Resistance mechanisms such as carbapenemase production can be difficult to identify quickly with phenotypic methods since confirmatory testing is often required.[6] Early recognition is crucial for infection control as well as treatment, but cultures may not provide results fast enough.[5]
4. Pseudomonas aeruginosa
This opportunistic pathogen is associated with hospital-acquired infections, particularly in immunocompromised patients.[1] It is highly adaptable and exhibits intrinsic resistance to many antibiotics.[4]
Treatment challenges: Pseudomonas often grows slowly in blood cultures,[6] and its diverse resistance mechanisms are not always obvious on routine susceptibility testing.[5] Rapid molecular methods can identify resistance genes leading to more targeted therapy early on.[7]
5. Candida species
Fungal bloodstream infections, most commonly due to Candida albicans and non-albicans Candida species, carry high mortality rates when diagnosis and treatment are delayed.[1]
Treatment challenges: Candida grows more slowly than bacteria in blood cultures, often taking several days to yield results.[6] Species-level identification is critical because fungal susceptibilities vary significantly depending on the species, but this also adds diagnostic delay.[7]
Why Faster Detection Matters
For all these pathogens, time to identification is critical. Delays in diagnosis can lead to prolonged empirical treatment with broad-spectrum antibiotics, increased risk of antimicrobial resistance, and serious clinical outcomes.[8],[5]
This is why molecular diagnostics are gaining traction in the fight against BSIs. By detecting pathogen DNA directly in the blood sample—often within just a few hours—molecular methods can identify organisms and resistance markers far sooner than traditional cultures.[9],[3] This enables clinicians to initiate or adjust targeted therapy much earlier, improving patient care and supporting antimicrobial stewardship.[1]
Key Takeaway
Pathogens such as S. aureus, E. coli, K. pneumoniae and P. aeruginosa remain leading causes of bloodstream infections, as well as Candida species causing the majority of yeast bloodstream infections, the greater challenge lies in the limitations of traditional diagnostic workflows. Delays in identification and susceptibility testing hinder effective treatment. Accelerating diagnosis with molecular methods has the potential to transform BSI management, supporting faster, more precise care.
At Microbio, our InfectID™-BSI test is designed to address earlier detection and identification of the most prevalent BSI pathogens. By directly detecting and identifying 26 sepsis-associated pathogens from blood samples in about 3 hours, InfectID™-BSI enables clinicians to move beyond waiting for blood cultures and make earlier, potentially targeted treatment decisions.
A shorter time to identification can strengthen antimicrobial stewardship efforts, potentially limit the use of broad-spectrum antibiotics, and ultimately lead to better patient outcomes.
References
- Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: A Review of Advances in Management. Adv Ther. 2017;34(11):2393-2411. doi:10.1007/s12325-017-0622-8[↩][↩][↩][↩][↩][↩][↩]
- Lamy B, Dargère S, Arendrup MC, Parienti JJ, Tattevin P. How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art. Front Microbiol. 2016;7:697. Published 2016 May 12. doi:10.3389/fmicb.2016.00697[↩]
- Kirn TJ, Weinstein MP. Update on blood cultures: how to obtain, process, report, and interpret. Clin Microbiol Infect. 2013;19(6):513-520. doi:10.1111/1469-0691.12180[↩][↩]
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6[↩][↩]
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi:10.1007/s00134-017-4683-6[↩][↩][↩][↩]
- Lamy B, Dargère S, Arendrup MC, Parienti JJ, Tattevin P. How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art. Front Microbiol. 2016;7:697. Published 2016 May 12. doi:10.3389/fmicb.2016.00697[↩][↩][↩][↩]
- Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490-526. doi:10.1128/CMR.00091-13[↩][↩]
- Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: A Review of Advances in Management. Adv Ther. 2017;34(11):2393-2411. doi:10.1007/s12325-017-0622-8[↩]
- Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490-526. doi:10.1128/CMR.00091-13[↩]